ECSP21052184A - Inhibidores de apol1 y sus métodos de uso - Google Patents

Inhibidores de apol1 y sus métodos de uso

Info

Publication number
ECSP21052184A
ECSP21052184A ECSENADI202152184A ECDI202152184A ECSP21052184A EC SP21052184 A ECSP21052184 A EC SP21052184A EC SENADI202152184 A ECSENADI202152184 A EC SENADI202152184A EC DI202152184 A ECDI202152184 A EC DI202152184A EC SP21052184 A ECSP21052184 A EC SP21052184A
Authority
EC
Ecuador
Prior art keywords
apol1
inhibitors
use methods
methods
ndkd
Prior art date
Application number
ECSENADI202152184A
Other languages
English (en)
Inventor
Jon H Come
Francois Denis
Kan-Nian Hu
Warren A Dorsch
Ales Medek
Leslie A Dakin
Martine Hamel
Brian Ledford
Tiansheng Wang
Yi Shi
Peter Rose
Faith Witkos
Kevin Gagnon
Suganthini S Nanthakumar
Elaine B Krueger
Olivier Nicolas
Jingrong Cao
Timothy J Senter
Muna Shrestha
Anne Fortier
Michael Brodney
Camil Sayegh
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of ECSP21052184A publication Critical patent/ECSP21052184A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La descripción proporciona al menos una entidad seleccionada de compuestos de la fórmula (I), formas en estado sólido de ellos, composiciones que los comprenden y métodos que los usan, incluyendo el uso en el tratamiento de glomeruloesclerosis segmentaria focal (FSGS) y/o enfermedad renal no diabética (NDKD).
ECSENADI202152184A 2018-12-17 2021-07-15 Inhibidores de apol1 y sus métodos de uso ECSP21052184A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862780667P 2018-12-17 2018-12-17

Publications (1)

Publication Number Publication Date
ECSP21052184A true ECSP21052184A (es) 2021-08-31

Family

ID=69182627

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202152184A ECSP21052184A (es) 2018-12-17 2021-07-15 Inhibidores de apol1 y sus métodos de uso

Country Status (24)

Country Link
US (3) US11618746B2 (es)
EP (1) EP3897833B1 (es)
JP (1) JP7573528B2 (es)
KR (2) KR102912203B1 (es)
CN (1) CN113453760B (es)
AR (1) AR116913A1 (es)
AU (1) AU2019405477B2 (es)
CA (1) CA3121910A1 (es)
CL (1) CL2021001561A1 (es)
CO (1) CO2021009053A2 (es)
CR (1) CR20210383A (es)
DO (1) DOP2021000116A (es)
EC (1) ECSP21052184A (es)
IL (2) IL319575A (es)
JO (3) JOP20210129A1 (es)
MA (1) MA54538A (es)
MX (1) MX2021007152A (es)
PE (1) PE20212302A1 (es)
SA (1) SA521422270B1 (es)
SG (1) SG11202105769XA (es)
TW (1) TWI848031B (es)
UA (1) UA128375C2 (es)
UY (1) UY38514A (es)
WO (1) WO2020131807A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113453760B (zh) 2018-12-17 2024-05-24 弗特克斯药品有限公司 Apol1抑制剂及其使用方法
AU2021213758A1 (en) * 2020-01-29 2022-09-01 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
WO2021158666A1 (en) * 2020-02-04 2021-08-12 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and methods of using same
US11801234B2 (en) * 2020-03-06 2023-10-31 Vertex Pharmaceuticals Incorporated Methods of treating APOL-1 dependent focal segmental glomerulosclerosis
CN116157393A (zh) * 2020-06-12 2023-05-23 弗特克斯药品有限公司 Apol1的抑制剂及其用途
EP4165023A1 (en) * 2020-06-12 2023-04-19 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and use of the same
CA3183591A1 (en) * 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and using the same
IL300298B2 (en) * 2020-08-26 2025-06-01 Vertex Pharma Inhibitors of apol1 and methods of using same
KR20230147137A (ko) * 2021-02-19 2023-10-20 메이즈 테라퓨틱스, 인코퍼레이티드 Apol1 저해제 및 이의 사용 방법
WO2023028237A1 (en) * 2021-08-26 2023-03-02 Vertex Pharmaceuticals Incorporated Solid forms of spirotricyclic apol1 inhibitors and methods of using same
WO2023101981A1 (en) * 2021-11-30 2023-06-08 Vertex Pharmaceuticals Incorporated Spirocyclic inhibitors of apol1 and methods of using same
MX2024008868A (es) 2022-01-18 2024-09-23 Maze Therapeutics Inc Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso.
JP2025505647A (ja) * 2022-02-08 2025-02-28 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｐｏｌ１阻害剤としての２－メチル－４’，５’－ジヒドロピロ［ピペリジン－４，７’－チエノ［２，３－ｃ］ピラン］誘導体、およびそれを使用する方法
WO2023194895A1 (en) 2022-04-06 2023-10-12 Glaxosmithkline Intellectual Property Development Limited Pyrrol derivatives as inhibitors of apolipoprotein l-1
EP4573077A1 (en) * 2022-08-19 2025-06-25 Maze Therapeutics, Inc. Apol1 inhibitors and methods of use
WO2025006262A1 (en) * 2023-06-29 2025-01-02 Omniab, Inc. Tetracyclic compounds containing a fused indole for treating apol1-mediated chronic kidney disease
GB202401326D0 (en) * 2024-02-01 2024-03-20 Podium Bio Ltd Novel compounds
KR20250122547A (ko) 2024-02-05 2025-08-14 서주사이언티픽 주식회사 AIoT 기반 방사성 동위원소 관리 시스템
WO2026012338A1 (zh) * 2024-07-09 2026-01-15 上海旭成医药科技有限公司 一种APOLs抑制剂

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4039676A (en) 1975-06-23 1977-08-02 Ciba-Geigy Corporation 2-piperidinoalkyl-1,4-benzodioxans
US6518423B1 (en) 1996-08-09 2003-02-11 Eisai Co., Ltd. Benzopiperidine derivatives
WO1999032482A1 (en) 1997-12-19 1999-07-01 Eli Lilly And Company Hypoglycemic imidazoline compounds
GB9905010D0 (en) 1999-03-04 1999-04-28 Merck Sharp & Dohme Therapeutic agents
AU7514700A (en) 1999-09-07 2001-04-10 Syngenta Participations Ag Cyanopiperidines
FR2801585B1 (fr) 1999-11-25 2002-02-15 Fournier Ind & Sante Nouveaux antagonistes des recepteurs de l'ii-8
GB0003397D0 (en) 2000-02-14 2000-04-05 Merck Sharp & Dohme Therapeutic agents
AU2002211828A1 (en) 2000-10-02 2002-04-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
FR2824826B1 (fr) 2001-05-17 2003-11-07 Fournier Lab Sa Nouveaux derives de 5-cyano-1h-indole antagonistes des recepteurs de l'interleukine-8
FR2824827B1 (fr) 2001-05-17 2004-02-13 Fournier Lab Sa Nouveaux derives de 5-phenyl-1h-indole antagoniste des recepteurs de l'interleukine-8
MXPA04004657A (es) 2001-11-14 2004-08-13 Teva Pharma Formas amorfas y cristalinas de potasio de losartan y proceso para su preparacion.
WO2003104180A1 (en) * 2002-06-05 2003-12-18 Natco Pharma Limited Process for the preparation of 4-(4-fluorobenzoyl) butyric acid
ATE496893T1 (de) 2002-12-20 2011-02-15 X Ceptor Therapeutics Inc Isochinolinonderivate und deren verwendung als medikamente
CA2537349A1 (en) 2003-09-03 2005-03-10 Galapagos Nv The claimed invention relates to novel 4-piperidinecarboxamide and the use thereof for the preparation of medicaments against 5-ht2a receptor-related disorders
US7728150B2 (en) 2004-03-03 2010-06-01 Eli Lilly And Company Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators
AR048523A1 (es) 2004-04-07 2006-05-03 Kalypsys Inc Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos
US20090088452A1 (en) 2005-11-22 2009-04-02 Coleman Paul J Indole Orexin Receptor Antagonists
US8222288B2 (en) 2006-08-30 2012-07-17 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
CA2666406A1 (en) 2006-10-16 2008-04-24 Gruenenthal Gmbh Substituted sulfonamide derivatives for use as bradykinin 1 receptor modulators
WO2008077810A2 (en) 2006-12-22 2008-07-03 F. Hoffmann-La Roche Ag Spiro-piperidine derivatives
MX2009008099A (es) * 2007-02-01 2009-12-14 Resverlogix Corp Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares.
EP2020414A1 (en) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
WO2009025478A1 (en) 2007-08-17 2009-02-26 Lg Life Sciences Ltd. Indole and indazole compounds as an inhibitor of cellular necrosis
MX2011012712A (es) 2009-05-29 2012-01-30 Raqualia Pharma Inc Derivados de carboxamida sustituidos con arilo como bloqueadores del canal de calcio o sodio.
KR101368130B1 (ko) 2009-11-16 2014-02-27 일라이 릴리 앤드 캄파니 Ｏｒｌ―１ 수용체 길항제로서의 스피로피페리딘 화합물
UA107943C2 (xx) 2009-11-16 2015-03-10 Lilly Co Eli Сполуки спіропіперидину як антагоністи рецептора orl-1
WO2012025155A1 (en) 2010-08-26 2012-03-01 Novartis Ag Hydroxamate-based inhibitors of deacetylases
BR102012024778A2 (pt) 2012-09-28 2014-08-19 Cristalia Prod Quimicos Farm Compostos heteroaromáticos; processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica
US10130632B2 (en) 2012-11-27 2018-11-20 Beth Israel Deaconess Medical Center, Inc. Methods for treating renal disease
JP2016531874A (ja) * 2013-09-26 2016-10-13 ファーマケア，インク． オートタキシン阻害剤化合物
ES2895490T3 (es) 2014-03-27 2022-02-21 Acad Medisch Ct Iminoazúcares N-(5-(bifen-4-ilmetiloxi)pentil)-sustituidos como inhibidores de glucosilceramida sintasa
CA2959437C (en) 2014-08-27 2018-03-06 The Governing Council Of The University Of Toronto Cannabinoid type 1 receptor modulators
WO2016055517A1 (en) 2014-10-08 2016-04-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Novel aminopyridine compounds useful as inhibitors of protein prenylation
EP3221314B1 (en) 2014-11-21 2019-07-03 Esteve Pharmaceuticals, S.A. Spiro-isoquinoline-1,4'-piperidine compounds having multimodal activity against pain
EP3858825A1 (en) 2015-08-27 2021-08-04 Pfizer Inc. Bicyclic-fused heteroaryl compounds as irak4 modulators
EP3414247B1 (en) 2016-02-08 2021-04-21 F. Hoffmann-La Roche AG Spiroindolinones as ddr1 inhibitors
EP3787669A4 (en) 2018-04-30 2022-03-30 The Trustees of Indiana University Compounds for modulating ddah and adma levels, as well as methods of using thereof to treat disease
IL316397A (en) 2018-05-22 2024-12-01 Ionis Pharmaceuticals Inc Modulators of APOL1 expression
CN113453760B (zh) 2018-12-17 2024-05-24 弗特克斯药品有限公司 Apol1抑制剂及其使用方法
US20220144838A1 (en) 2019-03-13 2022-05-12 Nanjing Immunophage Biotech Co., Ltd. Compounds as Inhibitors of Macrophage Migration Inhibitory Factor
JP2023508930A (ja) 2019-12-19 2023-03-06 カスマ セラピューティクス， インコーポレイテッド Ｔｒｐｍｌモジュレーター
AU2021213758A1 (en) 2020-01-29 2022-09-01 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
WO2021158666A1 (en) 2020-02-04 2021-08-12 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and methods of using same
US11801234B2 (en) 2020-03-06 2023-10-31 Vertex Pharmaceuticals Incorporated Methods of treating APOL-1 dependent focal segmental glomerulosclerosis
WO2021216665A1 (en) 2020-04-22 2021-10-28 Anima Biotech Inc. Collagen 1 translation inhibitors and methods of use thereof
WO2021220178A1 (en) 2020-04-29 2021-11-04 Cominnex Zrt. Iap antagonists and their therapeutic applications
WO2021224927A1 (en) 2020-05-07 2021-11-11 Rambam Med-Tech Ltd. Composition for use in the treatment of apol1-associated disease
CN116157393A (zh) 2020-06-12 2023-05-23 弗特克斯药品有限公司 Apol1的抑制剂及其用途
EP4165023A1 (en) 2020-06-12 2023-04-19 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and use of the same
CA3183591A1 (en) 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and using the same
IL300298B2 (en) 2020-08-26 2025-06-01 Vertex Pharma Inhibitors of apol1 and methods of using same
WO2023028237A1 (en) 2021-08-26 2023-03-02 Vertex Pharmaceuticals Incorporated Solid forms of spirotricyclic apol1 inhibitors and methods of using same
WO2023101981A1 (en) 2021-11-30 2023-06-08 Vertex Pharmaceuticals Incorporated Spirocyclic inhibitors of apol1 and methods of using same
US20230203000A1 (en) 2021-11-30 2023-06-29 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
AU2023218940A1 (en) 2022-02-08 2024-08-22 Vertex Pharmaceuticals Incorporated Spiro piperidine derivatives as inhibitors of apol1 and methods of using same
JP2025505647A (ja) 2022-02-08 2025-02-28 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｐｏｌ１阻害剤としての２－メチル－４’，５’－ジヒドロピロ［ピペリジン－４，７’－チエノ［２，３－ｃ］ピラン］誘導体、およびそれを使用する方法
CN118984821A (zh) 2022-02-08 2024-11-19 弗特克斯药品有限公司 作为apol1抑制剂的2-甲基-4-苯基哌啶-4-醇衍生物和其使用方法
CN119013281A (zh) 2022-02-08 2024-11-22 弗特克斯药品有限公司 作为apol1抑制剂的4'，5'-二氢螺[哌啶-4，7'-噻吩并[2，3-c]吡喃]衍生物和其使用方法

Also Published As

Publication number Publication date
BR112021011564A2 (pt) 2021-08-31
EP3897833A1 (en) 2021-10-27
SA521422270B1 (ar) 2024-02-18
CL2021001561A1 (es) 2021-11-26
US20200377479A1 (en) 2020-12-03
US11618746B2 (en) 2023-04-04
JOP20210131A1 (ar) 2023-01-30
AU2019405477A1 (en) 2021-06-24
SG11202105769XA (en) 2021-07-29
MX2021007152A (es) 2021-11-03
JP2022515369A (ja) 2022-02-18
US20250042878A1 (en) 2025-02-06
CA3121910A1 (en) 2020-06-25
IL283592A (en) 2021-07-29
CR20210383A (es) 2021-09-22
WO2020131807A1 (en) 2020-06-25
EP3897833B1 (en) 2026-02-04
US12060346B2 (en) 2024-08-13
US20230271945A1 (en) 2023-08-31
AU2019405477B2 (en) 2025-04-03
AR116913A1 (es) 2021-06-23
IL319575A (en) 2025-05-01
JOP20210129A1 (ar) 2023-01-30
UY38514A (es) 2020-07-31
TWI848031B (zh) 2024-07-11
CN113453760A (zh) 2021-09-28
KR20210116483A (ko) 2021-09-27
KR20260020195A (ko) 2026-02-10
DOP2021000116A (es) 2021-09-30
PE20212302A1 (es) 2021-12-10
MA54538A (fr) 2021-10-27
JOP20210130A1 (ar) 2023-01-30
JP7573528B2 (ja) 2024-10-25
KR102912203B1 (ko) 2026-01-16
IL283592B2 (en) 2025-08-01
TW202039471A (zh) 2020-11-01
CO2021009053A2 (es) 2021-08-09
UA128375C2 (uk) 2024-06-26
CN113453760B (zh) 2024-05-24
IL283592B1 (en) 2025-04-01

Similar Documents

Publication Publication Date Title
ECSP21052184A (es) Inhibidores de apol1 y sus métodos de uso
UY38403A (es) Moduladores de la alfa-1 antitripsina
MX2022014548A (es) Inhibidores de molecula de muerte programada 1 (pd-1)/ligando de molecula de muerte programada 1 (pd-l1).
CO2022008662A2 (es) Degradadores de smarca y usos de los mismos
CL2023000555A1 (es) Compuestos y métodos para el tratamiento de infecciones virales
CO2021013339A2 (es) Degradadores de stat y usos de los mismos
CL2023000662A1 (es) Agentes de rnai para inhibir la expresión de dux4, composiciones de los mismos y métodos de uso.
CO2018000631A2 (es) Compuestos bicíclicos como inhibidores de atx
BR112017002594A2 (pt) compostos inibidores de cinase de ligação de tank
CO2018000668A2 (es) Nuevos compuestos bicíclicos como inhibidores duales de atx/ca
ECSP099027A (es) Anticuerpos anti-dll4 y métodos que los usan
CR10069A (es) Anticuerpos anti-ox40l y métodos que los utilizan referencia cruzada con solicitudes relacionadas
CO2023014770A2 (es) Degradadores de cdk2 y sus usos
ECSP21026021A (es) Moduladores de la expresión de pnpla3
DK3962601T3 (da) 5-HT2A-agonister til anvendelse til behandling af depression
CR20200631A (es) Modulares de la expresión de apol1
CR20200089A (es) Compuestos espirocíclicos y sus métodos de preparación y uso
ECSP088743A (es) Anticuerpos para egfl7 y métodos para su uso
CO2022009691A2 (es) Formulaciones líquidas de tasimelteón y métodos para su uso
UY37702A (es) Combinaciones fungicidas
ES2609817T3 (es) Leucotoxina E/D como nuevo agente antiinflamatorio y microbicida
MX2022000654A (es) Sistemas fluorescentes para imagenes biologicas y usos de los mismos.
SV2018005701A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
CL2009000599A1 (es) Compuestos derivados de 4,5-dihidro-1h-pirazol(4,3-g)benzotiazol sustituidos; composicion farmaceutica; utiles para el tratamiento y prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunes, entre otras.
UY37261A (es) Formulación combinada de tres compuestos antivirales